<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25053">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899014</url>
  </required_header>
  <id_info>
    <org_study_id>NL43466.068.13</org_study_id>
    <secondary_id>2013-000456-17</secondary_id>
    <nct_id>NCT01899014</nct_id>
  </id_info>
  <brief_title>18F-choline PET-CT and MRI of Carotid Plaques</brief_title>
  <acronym>ParisK</acronym>
  <official_title>Plaque at Risk (ParisK): Molecular Imaging of Plaque Vulnerability Using 18F-choline PET-CT and MRI in Patients With Carotid Artery Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Translational Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating data in the literature suggests that radiolabeled-choline (18F-choline) is a
      sensitive molecular tracer for PET-CT imaging that is taken up in activated cells and, as
      such, is able to identify active inflammatory sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accumulation and subsequent activation of inflammatory cells in the atherosclerotic plaques
      play an essential role in transforming a stable plaque into a vulnerable plaque at risk to
      rupture. On this basis, the study aims to evaluate the diagnostic performance of 18F-choline
      PET-CT in identifying ongoing inflammation within atherosclerotic plaques. We hypothesize
      that 18F-choline is efficient in detecting intraplaque inflammation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>To correlate the 18F-choline uptake in the atherosclerotic plaque with the degree of intraplaque inflammation, as assessed on histology.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To correlate the intra-plaque 18F-choline uptake on PET with other histologic plaque parameters besides inflammation.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate the intra-plaque 18F-choline uptake on PET with atherosclerotic plaque parameters assessed on CT, MRI, and ultrasound.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare on PET the 18F-choline uptake in the symptomatic carotid plaque with the uptake in the asymptomatic contralateral carotid artery.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate a possible association between the degree of 18F-choline uptake on PET with patients' cardiovascular risk profile and medical history.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Plaque, Atherosclerotic</condition>
  <arm_group>
    <arm_group_label>18F-choline PET-CT imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.
Procedure: dynamic and static 18F-choline PET-CT imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-choline PET-CT imaging</intervention_name>
    <description>18F-choline PET-CT imaging</description>
    <arm_group_label>18F-choline PET-CT imaging</arm_group_label>
    <other_name>18F-fluormethylcholine</other_name>
    <other_name>[F18] choline</other_name>
    <other_name>[F18] fluormethylcholine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a female or male of ay race age &gt;18 years at the time of the
             investigational product administration (no maximum age);

          -  Informed consent by signing informed consent form regarding this study;

          -  Patients known with carotid artery stenosis &gt;50%, who are scheduled for carotid
             endarterectomy.

        Exclusion Criteria:

          -  Dementia, pregnancy, nursing mothers;

          -  Patients who do have a documented allergy for CT contrast media;

          -  Patients with a renal clearance &lt;45 ml/min/1.73m2 or &lt;60 ml/min/1.73m2 in patients
             with diabetes mellitus;

          -  Serious neurological deficits at symptomatic side (hemi paralysis, complete aphasia);

          -  Severe heart failure NYHA III-IV and severe pulmonary dysfunction dependent on oxygen
             supply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. E. Kooi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>S. A. Voo, MD, PhD</last_name>
    <phone>+31433877297</phone>
    <email>stefan.voo@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>S. A. Voo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ctmm.nl/en</url>
    <description>CTMM project</description>
  </link>
  <link>
    <url>http://www.ctmm.nl/en/projecten/hartvaat/parisk-1</url>
    <description>ParisK study</description>
  </link>
  <reference>
    <citation>Bucerius J, Schmaljohann J, Böhm I, Palmedo H, Guhlke S, Tiemann K, Schild HH, Biersack HJ, Manka C. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results. Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):815-20. doi: 10.1007/s00259-007-0685-x. Epub 2008 Jan 6.</citation>
    <PMID>18183393</PMID>
  </reference>
  <reference>
    <citation>Kato K, Schober O, Ikeda M, Schäfers M, Ishigaki T, Kies P, Naganawa S, Stegger L. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1622-8. doi: 10.1007/s00259-009-1152-7. Epub 2009 May 9.</citation>
    <PMID>19430785</PMID>
  </reference>
  <reference>
    <citation>Förster S, Rominger A, Saam T, Wolpers S, Nikolaou K, Cumming P, Reiser MF, Bartenstein P, Hacker M. 18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors: correlation in a PET-CT study. Nuklearmedizin. 2010;49(4):148-53. doi: 10.3413/nukmed-0299. Epub 2010 Jun 8.</citation>
    <PMID>20532464</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 20, 2013</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>18F-choline</keyword>
  <keyword>PET-CT</keyword>
  <keyword>MRI</keyword>
  <keyword>Ultrasound</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
